Spruce Biosciences (SPRB)
(Delayed Data from NSDQ)
$0.70 USD
0.00 (0.09%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.69 -0.01 (-1.68%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SPRB 0.70 0.00(0.09%)
Will SPRB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SPRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRB
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
SPRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should Know
Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?
Other News for SPRB
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Spruce Biosciences announces upcoming poster presentation
Spruce Biosciences’ Compliance Hurdle: Navigating Sarbanes-Oxley to Protect Market Value
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session